Vorstat 100mg (Vorinostat) is a histone deacetylase (HDAC) inhibitor manufactured by Pharma Lord. Vorinostat is used primarily in the treatment of cutaneous T-cell lymphoma (CTCL), particularly in patients whose disease is persistent, progressive, or recurrent. It works by inhibiting the action of enzymes called histone deacetylases, which play a role in regulating gene expression. This inhibition leads to the reactivation of genes that suppress cancer cell growth, resulting in cancer cell death.
Advantages of Vorinostat:
- Targeted Action: Vorinostat specifically targets histone deacetylases (HDACs), leading to the reactivation of tumor-suppressing genes and the inhibition of cancer cell growth.
- Effective for CTCL: It is highly effective in managing cutaneous T-cell lymphoma, especially in patients whose disease is resistant to other treatments.
- Promotes Cancer Cell Death: By affecting gene expression, Vorinostat helps to induce apoptosis (programmed cell death) in cancer cells.
- Oral Administration: Vorinostat is available in oral form, providing ease of use and greater patient convenience.
- Improves Quality of Life: It helps to manage symptoms and slow the progression of the disease, improving the overall quality of life in patients with CTCL.
Uses of Vorstat 100mg:
- Cutaneous T-cell Lymphoma (CTCL): Vorinostat is primarily used for the treatment of CTCL in patients who have failed to respond to other systemic therapies.
- Exploratory Use in Other Cancers: Vorinostat is being studied for potential use in other types of cancer, including non-Hodgkin lymphoma and solid tumors.